Why Supernus' Acquisition of Adamas Is a Smart Move

·2-min read

Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS). In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acquisition of Adamas is a smart move.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting